Docetaxel-Loaded Novel Nano-Platform for Synergistic Therapy of Non-Small Cell Lung Cancer

Xing Feng; Xiaoling Xiong; Shenglin Ma

doi:10.3389/fphar.2022.832725

Docetaxel-Loaded Novel Nano-Platform for Synergistic Therapy of Non-Small Cell Lung Cancer

Front Pharmacol. 2022 Mar 2:13:832725. doi: 10.3389/fphar.2022.832725. eCollection 2022.

Authors

Xing Feng^{1

2}, Xiaoling Xiong³, Shenglin Ma⁴

Affiliations

¹ Department of Thoracic Surgery, The Affiliated Hangzhou Hospital of Nanjing Medical University, Hangzhou, China.
² Department of Thoracic Surgery, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou, China.
³ Department of Nephrology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China.
⁴ Department of Oncology, The Affiliated Hangzhou Hospital of Nanjing Medical University, Hangzhou, China.

Abstract

Nowadays, non-small cell lung cancer (NSCLC) is threatening the health of all mankind. Although many progresses on treatment of lung cancer have been achieved in the past few decades, the current treatment methods are still traditional surgery, radiotherapy, and chemotherapy, which had poor selectivity and side effects. Lower-toxicity and more efficient treatments are in sore need. In this paper, a smart nanodelivery platform based on photothermal therapy, chemotherapy, and immunotherapy was constructed. The nanoparticles are composed of novel photothermal agents, Mn-modified phthalocyanine derivative (Mn^IIIPC), docetaxel (DTX), and an effective targeting molecule, hyaluronic acid. The nanoplatform could release Mn²⁺ from Mn^IIIPC@DTX@PLGA@Mn²⁺@HA(MDPMH) and probably activate tumor immunity through cGAS-STING and chemotherapy, respectively. Furthermore, DTX could be released in the process for removal of tumor cells. The "one-for-all" nanomaterial may shed some light on treating NSCLC in multiple methods.

Keywords: cGAS-STING; hotothermal therapy; immunotherapy; non-small cell lung cancer; targeted therapy.